Drug intelligence / Profile preview

LQ085

Development stage: Preclinical
Lead developer: Novamab Biopharmaceuticals
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

LQ085 is a preclinical-stage bispecific VHH nanobody being developed by Novamab for the treatment of autoimmune diseases. Utilizing Novamab's proprietary nanobody platform, LQ085 is designed for subcutaneous administration. While the specific molecular targets remain undisclosed, the drug is engineered as a bispecific agent, likely targeting two distinct epitopes or pathways involved in the pathogenesis of autoimmune conditions. As a VHH-based biologic, it offers potential advantages such as high stability, high affinity, and the ability to reach epitopes inaccessible to conventional antibodies.

Beyond the preview

Go deeper on LQ085.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LQ085.

Explore the full profile